Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 130Lymphoid 89Plasma cell 15Other hematologic neoplasm 10Tumor-Agnostic 5Gynecologic 4Breast 4Thoracic 3Gastrointestinal 3Other solid neoplasm 2Sarcoma 1Myeloid 1Dermatologic 1

Conditions

Neoplasms 4Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Prednisone × Tumor-Agnostic × Clear all
NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Constellation Pharmaceuticals

Phase 1/2 Completed
175 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Astellas Pharma Inc

Phase 2 Completed
60 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT06099990 2023-10-25

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Not yet recruiting
660 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

AEterna Zentaris

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡